Matthew Mackey

from Salem, MA

Get Report

Connected to:

Matthew Mackey Phones & Addresses

Salem, MA
9 Chandler St, Salem, MA 01970

Work

Company:

Eisai
Jun 2007 to Nov 2012
Address:

Andover, MA
Position:

Senior research investigator & principal scientist

Education

Degree:

Ph.D.
School / High School:

Dartmouth Medical School
1992 to 1997
Specialities:

Immunology

Industries

Pharmaceuticals

Lawyers & Attorneys

Matthew Mackey - Lawyer

view source

ISLN:

922699948

Admitted:

2009

Resumes

Drug Discovery | Immunology | Autoimmunity | Inflammation | Immuno-Oncology | In Vivo Pharmacology | Biomarkers

view source

Location:

Greater Boston Area

Industry:

Pharmaceuticals

Work:

Eisai - Andover, MA Jun 2007 - Nov 2012
Senior Research Investigator & Principal Scientist
Sanofi - Bridgewater, NJ Jan 2002 - May 2007
Research Investigator & Senior Research Investigator
National Institutes of Health - Bethesda, MD Jun 1998 - Dec 2001
Post-doctoral Fellow

Education:

Dartmouth Medical School 1992 - 1997
Ph.D., Immunology Colby College 1988 - 1991
B.S., Major: biology, Minor: chemistry University of Vermont 1987 - 1988

Name / Title

Company / Classification

Phones & Addresses

Matthew Mackey
Controller

Vesey, Inc.
Computer Maintenance and Repair

35 Myrtle St A, Boston, MA 02114

Matthew Mackey
Chief Financial Officer, General Manager

Computer Geeks
Computer Maintenance/Repair

35 Myrtle St, Boston, MA 02114

Matthew A. Mackey

TIMBER TOP FIREWOOD, LLC

Us Patents

Methods Of Use
view source
US Patent:

20100305098, Dec 2, 2010
Filed:

Nov 13, 2008
Appl. No.:

12/739334
Inventors:

Qian Chen - Andover MA, US
Jesse Cheng-Lin Chow - Hooksett NH, US
Fabian Gusovsky - Andover MA, US
Marc Lamphier - North Andover MA, US
Matthew Faust Mackey - Melrose MA, US
Kenzo Muramoto - Ibaraki, JP
Shawn Schiller - Haverhill MA, US
Christine J. Shaffer - Litchfield NH, US
Mark Spyvee - Hampstead NH, US
International Classification:

A61K 31/55
A61P 37/06
A61P 19/02
US Classification:

51421202
Abstract:

A method of treating a disorder such as rheumatoid arthritis or multiple sclerosis in a subject is carried out by administering to the subject a composition comprising a modulator compound of Th1 differentiation or Th17 expansion.

Selectively Substituted Quinoline Compounds
view source
US Patent:

20180354939, Dec 13, 2018
Filed:

Aug 22, 2018
Appl. No.:

16/108964
Inventors:

- Tokyo, JP
Hans Hansen - Somerville MA, US
Lynn Hawkins - Concord MA, US
Sally Ishizaka - Weston MA, US
Matthew Mackey - Melrose MA, US
Shawn Schiller - Haverhill MA, US
Chikako Ogawa - Basel, CH
Heather Davis - Haverhill MA, US
Atsushi Endo - Andover MA, US
Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo
International Classification:

C07D 417/14
C07D 403/14
C07D 413/04
C07D 401/10
C07D 401/14
C07D 471/10
C07D 487/10
C07D 471/04
C07D 215/48
C12Q 1/6897
G01N 33/50
C07D 451/04
C07D 487/04
C07D 493/10
C07D 413/14
Abstract:

Embodiments of the disclosure relate to selectively substituted quinolone compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Selectively Substituted Quinoline Compounds
view source
US Patent:

20180030045, Feb 1, 2018
Filed:

Aug 7, 2017
Appl. No.:

15/670904
Inventors:

- Tokyo, JP
Hans HANSEN - Somerville MA, US
Lynn HAWKINS - Concord MA, US
Sally ISHIZAKA - Weston MA, US
Matthew MACKEY - Melrose MA, US
Shawn SCHILLER - Haverhill MA, US
Chikako OGAWA - Basel, CH
Heather DAVIS - Haverhill MA, US
Atsushi ENDO - Andover MA, US
Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo
International Classification:

C07D 417/14
C07D 413/04
C07D 401/10
C07D 401/14
C07D 471/10
C07D 487/10
C07D 471/04
C07D 215/48
C12Q 1/68
G01N 33/50
C07D 451/04
C07D 487/04
C07D 493/10
C07D 413/14
C07D 403/14
Abstract:

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Selectively Substituted Quinoline Compounds
view source
US Patent:

20160326161, Nov 10, 2016
Filed:

Jul 27, 2016
Appl. No.:

15/220949
Inventors:

- Tokyo, JP
Hans HANSEN - Somerville MA, US
Lynn HAWKINS - Concord MA, US
Sally ISHIZAKA - Weston MA, US
Matthew MACKEY - Melrose MA, US
Shawn SCHILLER - Haverhill MA, US
Chikako OGAWA - Basel, CH
Heather DAVIS - Haverhill MA, US
Atsushi ENDO - Andover MA, US
Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo
International Classification:

C07D 417/14
C07D 413/04
C07D 471/10
C12Q 1/68
C07D 493/10
C07D 487/04
C07D 451/04
G01N 33/50
C07D 413/14
C07D 487/10
Abstract:

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Selectively Substituted Quinoline Compounds
view source
US Patent:

20160176841, Jun 23, 2016
Filed:

Oct 14, 2014
Appl. No.:

14/908164
Inventors:

- Bunkyo-ku, Tokyo, JP
Hans HANSEN - Somerville MA, US
Sally ISHIZAKA - Weston MA, US
Matthew MACKEY - Melrose MA, US
Shawn SCHILLER - Haverhill MA, US
Chikako OGAWA - Basel, CH
Sridhar NARAYAN - Belmont MA, US
Peter BERTINATO - Old Lyme CT, US
Gregory BERGER - East Lyme CT, US
Atsushi ENDO - Andover MA, US
Robert T. YU - Arlington MA, US
Lynn HAWKINS - Concord MA, US
Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo, OT
International Classification:

C07D 401/02
C07D 413/14
C07D 471/04
C07D 401/14
C07D 417/14
Abstract:

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Selectively Substituted Quinoline Compounds
view source
US Patent:

20150105370, Apr 16, 2015
Filed:

Oct 14, 2014
Appl. No.:

14/513556
Inventors:

- TOKYO, JP
HANS HANSEN - SOMERVILLE MA, US
LYNN HAWKINS - CONCORD MA, US
SALLY ISHIZAKA - WESTON MA, US
MATTHEW MACKEY - MELROSE MA, US
SHAWN SCHILLER - HAVERHILL MA, US
CHIKAKO OGAWA - BASEL, CH
HEATHER DAVIS - HAVERHILL MA, US
International Classification:

C07D 413/04
C07D 413/14
C07D 471/04
C07D 401/10
C07D 487/10
C07D 471/10
C07D 401/14
C07D 215/48
C07D 417/14
US Classification:

51421018, 544128, 546173, 5142352, 544122, 544121, 544 82, 5142325, 5142345, 544120, 540544, 51421115, 51421021, 540575, 514218, 540597, 51421707, 544 70
Abstract:

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.